Navigation Links
Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
Date:6/29/2012

THE WOODLANDS, Texas, June 29, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today the publication of results from two initial trials of LX4211 in patients with type 2 diabetes in the online edition of the journal Clinical Pharmacology & Therapeutics. The paper, containing results from both trials, is entitled, "LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients with Type 2 Diabetes in a Randomized, Placebo-controlled Trial," and will also appear in an upcoming print edition of the journal. A link to the online article can be accessed at http://www.nature.com/clpt/journal/vaop/ncurrent/full/clpt201258a.html.

"This publication represents the first peer-reviewed description of SGLT1 inhibition stimulating GLP-1 and PYY release in man," said Dr. Brian Zambrowicz, Lexicon's executive vice president and chief scientific officer. "Since LX4211 also inhibits SGLT2, the rapid and significant glycemic control and metabolic benefits observed may be attributed to effective dual inhibition of these two targets."

In the 4-week Phase 2a study described in the paper, 36 patients received once-daily oral administration of placebo or 150 mg or 300 mg of LX4211 (randomized 1:1:1) in an in-patient setting. Patients receiving LX4211 exhibited rapid and significant improvements relative to placebo in multiple measures of glycemic control, including hemoglobin A1c (HbA1c), fasting plasma glucose, and oral glucose tolerance. In addition, serum triglycerides were significantly lower at the end of the four-week treatment period, and trends of meaningful reductions in body weight an
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
2. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
3. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
4. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
5. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
6. Lexicon to Provide First Quarter 2012 Financial Results
7. Medivir Announces an Interferon-Free Phase II Combination Trial With TMC435 and daclatasvir to Commence Shortly
8. Hanger, Inc. Announces Second Quarter 2012 Earnings Release Conference Call
9. ResMed Announces Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year-End 2012 Results
10. Marshall Edwards Announces Name Change to MEI Pharma ("MEIP")
11. Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, ... US Patent and Trademark Office (USPTO) has issued ... a dendritic cell-based immunotherapeutic vaccine targeting six tumor ... claims of US Patent No. 8,871,211, which issued ... cancer by administering a dendritic cell composition comprising ...
(Date:12/17/2014)... KENNESAW, Ga. and RALEIGH, ... Clinical Trial Marketing Communications, LLC (CTMC), and Integrated ... in patient recruitment and retention for clinical trials ... called Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS ... and retention services to pharmaceutical, biotechnology and medical ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "MEMS Gyroscopes Analog Devices ... report to their offering. ... for tactical grade applications made a lot of ... of reliability. They are now accepted in high-reliability ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... Glycotex, Inc., a clinical stage biopharmaceutical company, announced ... of the two completed Phase II clinical studies ... the clinicaltrials.gov database.  These clinical studies have evaluated ... in patients undergoing carbon dioxide laser skin resurfacing. ...
... Street Healthcare Partners , a strategic private equity firm ... has acquired MarketLab, Inc.  Water Street,s investment ... healthcare distribution sector.  The acquisition expands Water Street,s current ... sciences, medical devices and services to 13. ...
Cached Medicine Technology:Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101 2Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101 3Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101 4Water Street Healthcare Partners Acquires MarketLab, Inc. 2Water Street Healthcare Partners Acquires MarketLab, Inc. 3
(Date:12/19/2014)... (PRWEB) December 20, 2014 Sweetdressy.com ... market, has introduced its newest selection of cheap prom ... are very popular in the world and clients can ... , Meanwhile, these prom dresses feature cool cuts and ... $200 now, targeting the middle-end market. Discount shipping costs ...
(Date:12/19/2014)... 19, 2014 The Plantrician ... developing educational events, tools and resources for healthcare ... School , the world’s leading online cooking school, ... human being needs: Culinary Rx. As an online ... Culinary Rx, scheduled for debut spring 2015, will ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Eufaula, Oklahoma, ... to Lake Eufaula, the state’s largest lake with more ... town is home to a little more than 3,000 ... P.M. on Saturday, the 6th of December. , Featuring ... way through downtown Eufaula on Main Street. Narconon ...
(Date:12/19/2014)... 2014 The Medspa at Hendrick in ... from respected cosmetic brand Juvéderm. Voluma XC treats volume ... The Medspa at Hendrick is pleased to be able ... technology to its clients. , Voluma is the first ... to treat the mid-face and cheek area. This non-invasive ...
(Date:12/19/2014)... News) -- The intestinal bacteria that cause inflammatory bowel ... be inherited, researchers report. The findings, published recently ... in efforts to prevent the disease and treat the ... authors added. "The intestinal bacteria, or ,gut microbiome, ... a big impact on your health for the rest ...
Breaking Medicine News(10 mins):Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2
... American parents may want to think again about how ... germs. A new Northwestern University study done in ... inflammation -- associated with diseases of aging like cardiovascular ... of adults in the United States have chronically elevated ...
... 30 (HealthDay News) -- Elevated blood sugar levels may ... The new study included nearly 6,900 patients, average age ... and private practices in Austria, Germany and Switzerland between ... leading infectious diseases in industrialized nations, is a major ...
... research shows that it is beneficial to have a ... new study led by researchers at the Johns Hopkins ... be true for older adults suffering from poor mental ... care visits helps or hinders physician visit processes and ...
... skin transplant surgery is safe and effective for restoring skin ... first study of its kind in the United States, researchers ... and found that the treated area regained on average 43 ... localized vitiligo, the treated area regained on average ,68 percent ...
... Philadelphia, PA, May 30, 2012 Bipolar disorder is ... swings in mood between mania and depression. The episodes ... months, and the risk of suicide is high. ... prevent the depressive episodes, but they are not universally ...
... (HealthDay News) -- Even after they shed their excess pounds, ... according to a new study. Researchers asked young women ... 70 pounds of excess weight or had stayed the same ... thin. The participants were then asked about some of ...
Cached Medicine News:Health News:Understanding the links between inflammation and chronic disease 2Health News:Understanding the links between inflammation and chronic disease 3Health News:Patient mental health overlooked by physician when a family member is present 2Health News:Skin transplant offers new hope for vitiligo patients 2Health News:Ketamine improved bipolar depression within minutes 2Health News:Once-Obese Women Still Face Stigma, Study Finds 2
... and comfortable eye protection Properly manufactured ... of scatter radiation. Our high quality frames ... comfort with minimized weight. Our lenses are ... that meet all industry standards. Most Pulse ...
... with the safety and comfort of the practitioner ... called SF-6) leaded glass, the industry standard for ... set for optical clarity, visible light transmission, power ... protecting your eyes, it also helps you look ...
Uvex Patriot Frame...
... Both lenses and frames are designed with ... mind. Our lenses are Schott RS-520 (also called ... shielding glass. These lenses meet standards, as set ... prism correction. ,While our eyewear is protecting ...
Medicine Products: